Journal
JOURNAL OF LIPID RESEARCH
Volume 60, Issue 12, Pages 2020-2033Publisher
ELSEVIER
DOI: 10.1194/jlr.RA119000100
Keywords
CXC chemokine ligand 12; CXC chemokine receptor 4; ATP binding cassette transporter A1; cholesterol efflux; glycogen synthase kinase 3 beta; transcription factor 21
Categories
Funding
- Hunan Provincial Innovation Foundation for Postgraduate Grant [CX20190750]
- National Natural Science Foundation of China [81770461]
Ask authors/readers for more resources
CXC chemokine ligand 12 (CXCL12) is a member of the CXC chemokine family and mainly acts on cell chemotaxis. CXCL12 also elicits a proatherogenic role, but the molecular mechanisms have not been fully defined yet. We aimed to reveal if and how CXCL12 promoted atherosclerosis via regulating lipid metabolism. In vitro, our data showed that CXCL12 could reduce ABCA1 expression, and it mediated cholesterol efflux from THP-1-derived macrophages to apoA-I. Data from the luciferase reporter gene and chromatin immunoprecipitation assays revealed that transcription factor 21 (TCF21) stimulated the transcription of ABCA1 via binding to its promoter region, which was repressed by CXCL12. We found that CXCL12 increased the levels of phosphorylated glycogen synthase kinase 3 beta (GSK3 beta) and the phosphorylation of beta-catenin at the Thr120 position. Inactivation of GSK3 beta or beta-catenin increased the expression of TCF21 and ABCA1. Further, knockdown or inhibition of CXC chemokine receptor 4 (CXCR4) blocked the effects of CXCL12 on TCF21 and ABCA1 expression and the phosphorylation of GSK3 beta and beta-catenin. In vivo, the overexpression of CXCL12 in Apoe(-/-) mice via lentivirus enlarged the atherosclerotic lesion area and increased macrophage infiltration in atherosclerotic plaques. We further found that the overexpression of CXCL12 reduced the efficiency of reverse cholesterol transport and plasma HDL-C levels, decreased ABCA1 expression in the aorta and mouse peritoneal macrophages (MPMs), and suppressed cholesterol efflux from MPMs to apoA-I in Apoe(-/-) mice. Collectively, these findings suggest that CXCL12 interacts with CXCR4 and then activates the GSK-3 beta/beta-catenin(T120)/TCF21 signaling pathway to inhibit ABCA1-dependent cholesterol efflux from macrophages and aggravate atherosclerosis. Targeting CXCL12 may be a novel and promising strategy for the prevention and treatment of atherosclerotic cardiovascular diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available